Biopharmaceutical Manufacturing in India, China and South Korea - Regulatory Framework, Infrastructure Support and Discovery Funding Create an Environment Conducive to Growth

Document Sample
Biopharmaceutical Manufacturing in India, China and South Korea - Regulatory Framework, Infrastructure Support and Discovery Funding Create an Environment Conducive to Growth Powered By Docstoc
					Biopharmaceutical Manufacturing in India, China
and South Korea
Regulatory Framework, Infrastructure Support and Discovery Funding Create
an Environment Conducive to Growth
GBI Research Report Guidance




                                              GBI Research Report Guidance
                                              The report provides an analysis of the biopharmaceuticals approved in 2010 and 2011, operating dynamics
                                              in the biopharmaceutical industry, the current scenario in biopharmaceutical manufacturing, key
                                              stakeholders, the value of biopharmaceutical markets, and forecasts for India, China, South Korea, and the
                                              global market. Also covered are the trends witnessed in biopharmaceutical manufacturing, the preferred
                                              partnership pricing model, contract manufacturing partnerships, a comparative analysis of
                                              biopharmaceutical manufacturing in India, China and South Korea, and their competitive landscapes.
                                              ·     Chapter three, titled Overview of the Biopharmaceutical Industry, presents an objective analysis of
                                                    newly approved biopharmaceuticals, the current scenario in biopharmaceutical manufacturing, factors
                                                    driving outsourcing to India, China and South Korea, drivers for CRAMS, contract manufacturing
                                                    benefits, operating cost analysis, manufacturing equipment trends, comparative analysis of new and
                                                    old equipment, biosimilars in Asia, trends witnessed in biopharmaceutical manufacturing, the contract
                                                    pricing model, and contract manufacturing partnerships.
                                              ·     Chapter four analyzes biopharmaceuticals in India, the augmentation potential for biopharmaceuticals
                                                    to grow in India, the biopharmaceutical market drivers and barriers, a regulatory overview, and the
                                                    competitive landscape.
                                              ·     Chapter five, titled Overview of Biopharmaceutical Manufacturing in China, covers the Chinese
                                                    biopharmaceuticals market, economic impact, biopharmaceuticals under progression in China,
                                                    challenges faced by the biopharmaceuticals industry, the contract manufacturing scenario, and the
                                                    competitive landscape.
                                              ·     Chapter six presents an overview of biopharmaceuticals in South Korea, including the evolution of
                                                    biopharmaceuticals, drivers, market size, major R&D achievements, South Korea’s strategic advantages
                                                    over India and China, and the competitive landscape
                                              ·     Chapter seven presents the appendix.




  © GBI Research. This is a licensed product and is not to be photocopied                                                  GBIHC255MR / Published OCT 2012
                                                                                                                                                    Page 2
Executive Summary




                                              Executive Summary
                                              Biopharmaceuticals Show Consistent Growth in Revenues
                                              The annual revenue for biopharmaceuticals has been consistently growing since 2001, accounting for 15.6%
                                              of the total pharmaceutical market in 2011. The global biopharmaceutical market was valued at $138 billion
                                              in 2011 and is expected to grow to over $320 billion by 2020. By 2014, biosimilars are expected to enter the
                                              US market, and GBI Research estimates that they have significant potential for growth in the
                                              biopharmaceutical sector, reaching $9 billion by 2020.

                                                Biopharmaceutical Manufacturing, Percentage of Biopharmaceuticals in the Global Pharmaceutical
                                                Market, 2001-2011

                                                                                         2,000                                                                                                     18




                                                                                                                                                                                                        Biopharmaceutical market as (%) of global pharmaceutical market
                                                                                         1,800                                                                                                     16

                                                                                         1,600                                                                                              15.6
                                                                                                                                                                                      15           14
                                                                                                                                                                             14.4
                                                    Global pharmaceutical market ($bn)




                                                                                                                                                                    13.8
                                                                                         1,400                                                             13.1
                                                                                                                                                                                                   12
                                                                                                                                                  12
                                                                                         1,200
                                                                                                                                        10.8                                                       10
                                                                                         1,000                                  9.9
                                                                                                                      9.1                                                                   889
                                                                                                                                                                                    855
                                                                                                              8.7                                                          812                     8
                                                                                                                                                                  770
                                                                                          800     7.8                                                   727
                                                                                                                                               684
                                                                                                                                       641
                                                                                                                             599                                                                   6
                                                                                          600                       560
                                                                                                           523
                                                                                                 489
                                                                                                                                                                                                   4
                                                                                          400


                                                                                          200                                                                                                      2


                                                                                            0                                                                                                      0
                                                                                                 2001      2002     2003    2004       2005    2006    2007       2008     2009     2010   2011

                                                                                                        Global pharmaceutical market     % of biopharmaceutical in global pharmaceutical market

                                                Source: GBI Research; Gao, 2011




                                              GBI Research believes that the next decade will bring about a paradigm shift in biomanufacturing
                                              technologies, with improvements in equipment efficiency and the introduction of novel therapies. In
                                              pharmerging countries such as India, China and South Korea, the emergence of biosimilars is seen as a key
                                              macroeconomic factor for generating revenues by attracting Foreign Direct Investment (FDI) in the start-up
                                              of manufacturing units. Efficient manufacturing processes and equipment will reduce production costs,
                                              provide economic benefits and decrease healthcare expenditure. The US has the most advanced R&D in
                                              biopharmaceutical manufacturing, and most biopharmaceuticals are licensed first in the US. The approval of
                                              biopharmaceuticals has contributed significantly to the US economy and has saved many from life-
                                              threatening diseases.




  © GBI Research. This is a licensed product and is not to be photocopied                                                                                                   GBIHC255MR / Published OCT 2012
                                                                                                                                                                                                     Page 3
Executive Summary




                                              Single-Use Bioprocessing and Microbial Technologies to Dominate Biopharmaceutical Manufacturing
                                              Pharmaceutical companies, in the process of standardizing production technology, are installing single use
                                              bioprocessing gears at manufacturing locations. Biopharmaceutical manufacturers are increasingly shifting
                                              their focus to disposable bioprocessing equipment, which is mostly used in upstream manufacturing. The
                                              adoption of this equipment is in the initial stages, and GBI Research expects robust growth potential in the
                                              foreseeable future. This equipment is also finding application in preclinical and clinical trials.
                                              Microbial manufacturing technology is relatively more acceptable and well proven. It has been under
                                              continuous development, and has led to the discovery of new subsidiary technologies. Recombinant
                                              proteins produced by mammalian cell culture processes are gaining significant traction by the
                                              pharmaceutical players, and biopharmaceuticals from these proteins have been successful in generating
                                              revenues of more than $1 billion. GBI Research believes these two technologies are the hallmark of
                                              biopharmaceutical manufacturing and are set to further advance the manufacturing process.
                                              Biosimilars in Asia
    Emerging economies, such
                                              Emerging economies, such as India and China, have developed regulatory approval guidelines which are
    as India and China, have
                                              relatively less stringent than their western counterparts. Lenient regulations and tax incentives during the
    developed regulatory
                                              initial industrial phase attracted industry players to operate in the region. For example, major supporters of
    approval guidelines which
                                              the biopharmaceutical industry in India, such as Biocon and Dr Reddy’s Laboratories; and China-based
    are relatively less stringent
                                              companies, such as Hualan Biological Engineering and Shanghai Kehua Bio-Engineering, are planning large-
    than their western
                                              scale product distribution strategies in western countries. Biosimilars of some of the biologics that are
    counterparts
                                              currently under exclusivity in western countries, such as Enbrel and Rituxan, are sold in developing
                                              countries.
                                              The South Korean government has announced capital and institutional support to boost biopharmaceutical
                                              manufacturing, and has set an ambitious target of acquiring a 22% global biosimilars market share by 2020.
                                              The Samsung Corporation, which operates in the electronics industry, has ventured into the biosimilar
                                              industry, and plans to invest over $2 billion before 2020. It has entered into a partnership with the Quintiles
                                              Corporation, and the joint venture will be functional by 2013. It will initially manufacture
                                              biopharmaceuticals on a contract basis, and plans to launch biosimilar versions of Humira, Enbrel and
                                              Remicade after their patents expire in 2016. Similarly, an Indian company called Cipla invested $65m in the
                                              biotech company MabPharm to build biologic-manufacturing facilities. The Chinese company AutekBio has
                                              stayed one step ahead of its competitors by securing the FDA and European Medical Agency (EMA)
                                              certifications needed to produce biopharmaceuticals.
                                              Nine Companies Account for 79% of Global Biopharmaceutical Production
    Globally, 79% of
    biopharmaceutical                         The new biological entity market is estimated to grow at a rate of 7% until 2015. Globally, 79% of
    production is under the                   biopharmaceutical production is under the management of nine companies, and more than 60% of this
    management of nine                        share is produced from manufacturing plants located in the US. However, as demand is projected to
    companies, and more than                  escalate in Asian economies, companies are expanding their manufacturing capacities, or strategically
    60% of this share is                      investing in these economies, to manufacture biopharmaceuticals.
    produced from
    manufacturing plants
    located in the US




  © GBI Research. This is a licensed product and is not to be photocopied                                                     GBIHC255MR / Published OCT 2012
                                                                                                                                                       Page 4
Executive Summary




                                                Biopharmaceutical Manufacturing, Global, Production Capacity by Company (%), 2011

                                                                                           Others
                                                                                           21.3%                       Roche
                                                                                                                       25.0%




                                                                              Novartis
                                                                               5.1%


                                                                               Eli Lilly                                       Johnson & Johnson
                                                                                5.2%                                                 8.8%

                                                                                     Sanofi
                                                                                     5.5%
                                                                                                                       Boehringer Ingelheim
                                                                                              Pfizer                          8.5%
                                                                                              5.9%
                                                                                                       Lonza   Amgen
                                                                                                       6.5%     8.2%



                                                Source: GBI Research; Levine, 2011




                                              Roche is the global leader in biopharmaceutical manufacturing, with 25% of the global biologic production
                                              capacity. Roche’s manufacturing network comprises 19 sites, of which five sites are in Asia, with three in
                                              Japan and one each in Singapore and China. Roche produces some of the top blockbuster biologics, such as
                                              Rituxan, Avastin and Herceptin, with combined sales of $19.5 billion in 2011.
                                              Johnson & Johnson has the second largest biologic production capacity, and it is making concerted efforts to
                                              enhance the quality of the manufacturing systems at its other sites. To expand its production base, it
                                              acquired Crucell NV, a biopharmaceutical company focused on the R&D and production of vaccines and
                                              antibodies, in 2011.
                                              Boehringer Ingelheim, in an attempt to increase its presence in emerging economies, announced in 2009 its
                                              plan to invest $120m in a phased manner, over a period of several years, in Asia. In 2010, the company
                                              invested $13.2m in building the Center of Competence in Shanghai, which specializes in the quality control
                                              of pharmaceutical raw ingredients procured in China. In 2011, it decided to expand the production site at
                                              Zhangjiang Hi-tech Park in Shanghai with an investment of $94.8m. The company has manufacturing sites in
                                              Biberach, Germany, Vienna and Austria; in addition to this, the company purchased a production site in
                                              California from Amgen, and integrated it within the existing production network in 2011.
                                              In order to optimize manufacturing operations, Amgen has started multiple initiatives, including the
                                              construction of new formulation and fill facilities and the expansion of the bulk protein facilities at their
                                              Puerto Rico site, and the expansion of their newly acquired formulation, fill-and-finish sites in Ireland.
                                              Lonza has 12 manufacturing sites spanning three continents, with the majority of its manufacturing capacity
                                              established in the US. In Asia, it has facilities in Singapore and China. In GBI Research’s view, the South
                                              Korea-based company Celltrion is a strong contender for a place in the top nine companies by 2017. Its
                                              existing mammalian cell culture and purification capacity is 50,000 liters, and the company is planning to
                                              incorporate an additional 90,000 liters in 2012.




  © GBI Research. This is a licensed product and is not to be photocopied                                                                 GBIHC255MR / Published OCT 2012
                                                                                                                                                                   Page 5
Table of Contents




                                              1          Table of Contents
                                              1 Table of Contents ........................................................................................................................................ 6
                                                1.1      List of Tables .................................................................................................................................... 8
                                                1.2      List of Figures................................................................................................................................... 9
                                              2 Biopharmaceutical Manufacturing in India, China and South Korea - Introduction ................................. 11
                                                2.1      Introduction................................................................................................................................... 11
                                              3 Biopharmaceutical Manufacturing in India, China and South Korea - Overview of the Biopharmaceutical
                                                Industry ..................................................................................................................................................... 12
                                                3.1      Definition and Objective Analysis of Newly Approved Biopharmaceuticals .................................. 12
                                                3.2      Collective Analysis of Biopharmaceuticals Approved in 2010 and 2011 ....................................... 15
                                                3.3      Current Scenario in Biopharmaceutical Manufacturing ................................................................ 17
                                                3.4      Biopharmaceutical Manufacturing ................................................................................................ 22
                                                3.5      Factors Driving Outsourcing to India, China and South Korea ....................................................... 23
                                                    3.5.1      Comparative Cost Analysis between In-House Biopharmaceutical Production Versus Contract
                                                               Manufacturing Organizations ............................................................................................... 23
                                                3.6      Growth Drivers for Contract Research and Manufacturing Services ............................................. 24
                                                3.7      Contract Manufacturing Benefits .................................................................................................. 26
                                                3.8      Operating Cost Analysis in Biopharmaceutical Manufacturing ..................................................... 27
                                                    3.8.1      Labor Cost Analysis................................................................................................................ 27
                                                    3.8.2      Investment Cost Analysis ....................................................................................................... 28
                                                    3.8.3      Standard Operating Costs ..................................................................................................... 29
                                                3.9      Cost and Timeline Analysis for Therapeutic Monoclonal Antibody Product Development ........... 31
                                                3.10 Manufacturing Equipment Trends ................................................................................................ 34
                                                3.11 Comparative Analysis of New and Old Equipment ........................................................................ 35
                                                3.12 Consolidation in Pharmaceutical Industry has Resulted in Idle Production Lines ......................... 36
                                                3.13 Biosimilars in Asia .......................................................................................................................... 38
                                                3.14 CMOs to Benefit by Expanding Operations in Biopharmaceutical Manufacturing ........................ 38
                                                3.15 Trends Witnessed in Biopharmaceutical Manufacturing .............................................................. 39
                                                    3.15.1 Single-Use Bioprocessing and Microbial Technologies to Dominate Biopharmaceutical
                                                               Manufacturing ...................................................................................................................... 39
                                                    3.15.2 Biopharmaceutical R&D and Manufacturing Outsourcing to Rise ........................................ 39
                                                    3.15.3 Market for Biopharmaceuticals to Rise at Brisk Rate ............................................................ 39
                                                    3.15.4 Introduction of Biosimilars to Multiply Biopharmaceutical Manufacturers .......................... 39
                                                    3.15.5 R&D Spend in Biopharmaceuticals Insulated from Economic Downturn ............................... 40
                                                    3.15.6 Downstream Processing Technologies Acting as Bottleneck in Biopharmaceutical
                                                               Manufacturing ...................................................................................................................... 40
                                                3.16 Preferred Biopharmaceutical Contract Pricing Model ................................................................... 40
                                                3.17 Contract Manufacturing Partnerships ........................................................................................... 41
                                                3.18 Comparative Analysis of India, China and South Korea with Reference to Government Initiatives,
                                                         Investment and Skills ..................................................................................................................... 43
                                              4 Biopharmaceutical Manufacturing in India, China and South Korea - Overview of Biopharmaceutical
                                                Manufacturing in India .............................................................................................................................. 44
                                                4.1      Augmentation Potential of Biopharmaceuticals in India ............................................................... 44
                                                    4.1.1      Stem Cells .............................................................................................................................. 44
                                                    4.1.2      Biosimilars ............................................................................................................................. 44
                                                    4.1.3      Vaccines ................................................................................................................................ 46
                                                4.2      Biopharmaceutical Revenues in India ........................................................................................... 47
                                                4.3      Drivers and Barriers for Biopharmaceutical Manufacturing in India ............................................. 48
                                                4.4      Proposals to the Government for Promoting Biopharmaceutical Manufacturing ........................ 49
                                                4.5      Pharmaceutical Cluster Development in India .............................................................................. 49
                                                4.6      Regulatory Overview for Biopharmaceuticals in India .................................................................. 50
                                                4.7      Competitive Landscape ................................................................................................................. 51


  © GBI Research. This is a licensed product and is not to be photocopied                                                                                          GBIHC255MR / Published OCT 2012
                                                                                                                                                                                            Page 6
Table of Contents




                                                    4.7.1     Biocon Ltd. ............................................................................................................................. 51
                                                    4.7.2     Serum Institute of India Ltd. .................................................................................................. 52
                                                    4.7.3     Panacea Biotec Ltd ................................................................................................................ 53
                                                    4.7.4     Dr. Reddy’s ............................................................................................................................ 54
                                                    4.7.5     Cipla ...................................................................................................................................... 55
                                                    4.7.6     Lupin ...................................................................................................................................... 56
                                              5 Biopharmaceutical Manufacturing in India, China and South Korea - Overview of Biopharmaceutical
                                                Manufacturing in China ............................................................................................................................. 57
                                                5.1      Market Size for Chinese Biopharmaceuticals ................................................................................ 57
                                                5.2      Economic Impact of Biopharmaceuticals Approved in China ........................................................ 59
                                                5.3      Biopharmaceuticals under Progression in China ........................................................................... 61
                                                    5.3.1     Antibodies ............................................................................................................................. 61
                                                    5.3.2     Long-acting Proteins ............................................................................................................. 61
                                                    5.3.3     Gene Therapy Products ......................................................................................................... 61
                                                    5.3.4     New vaccines ......................................................................................................................... 61
                                                5.4      Challenges Faced by Biopharmaceuticals in China ........................................................................ 62
                                                    5.4.1     Overproduction of Simpler Drugs is Leading to Over-Competition in Domestic Markets ...... 62
                                                    5.4.2     Weak Strategic Planning and Management Skills ................................................................. 62
                                                    5.4.3     Expression Deficit to Limit the Development and Industrialization of Biopharmaceuticals .. 62
                                                5.5      Propositions for the Advancement of Biopharmaceuticals in China ............................................. 62
                                                    5.5.1     Internationalize the Regulatory System to Eliminate Deficiencies for Biopharmaceutical
                                                              Products ................................................................................................................................ 62
                                                    5.5.2     Breakthrough Innovation is Critical for the Success of Biopharmaceuticals .......................... 62
                                                    5.5.3     Set up Industrial Standards and Fortify Manufacturing Capacity.......................................... 62
                                                    5.5.4     Augment Communication Between Researchers and Clinicians for Developing
                                                              Biopharmaceuticals ............................................................................................................... 63
                                                5.6      Contract Manufacturing Scenario in China.................................................................................... 63
                                                5.7      Competitive Landscape ................................................................................................................. 64
                                                    5.7.1     Hualan Biological Engineering Co., Ltd.................................................................................. 64
                                                    5.7.2     Shanghai Kehua Biological Engineering Co., Ltd. .................................................................. 65
                                                    5.7.3     Beijing Tiantan Biological Products Co., Ltd. ......................................................................... 66
                                                    5.7.4     Beijing SL Pharmaceutical Co., Ltd. ....................................................................................... 67
                                                    5.7.5     Shanghai RAAS Blood Products Co., Ltd. ............................................................................... 68
                                              6 Biopharmaceutical Manufacturing in India, China and South Korea - Overview of Biopharmaceutical
                                                Manufacturing in South Korea .................................................................................................................. 69
                                                6.1      South Korean Biopharmaceutical Industry .................................................................................... 69
                                                6.2      Market Size for South Korean Biopharmaceuticals ....................................................................... 70
                                                6.3      Evolution of the Biopharmaceutical Industry in South Korea........................................................ 71
                                                6.4      Korean Free Trade Agreement with the US ................................................................................... 71
                                                6.5      Drivers Affecting Biopharmaceuticals in South Korea ................................................................... 72
                                                    6.5.1     Korea/US Free Trade Agreement........................................................................................... 72
                                                    6.5.2     Punishment Systems and Price Reduction ............................................................................. 72
                                                    6.5.3     Government Initiatives for the Development of the Biopharmaceutical Industry ................. 72
                                                6.6      Major R&D Achievements in South Korea ..................................................................................... 72
                                                6.7      South Korea’s Strategic Advantage over India and China.............................................................. 72
                                                6.8      Competitive Landscape ................................................................................................................. 73
                                                    6.8.1     Celltrion ................................................................................................................................. 73
                                                    6.8.2     LG Life Sciences ..................................................................................................................... 74
                                                    6.8.3     Hanwha Chemical ................................................................................................................. 75
                                                    6.8.4     ISU Abxis ................................................................................................................................ 76
                                                    6.8.5     Green Cross ........................................................................................................................... 77
                                              7 Biopharmaceutical Manufacturing in India, China and South Korea - Appendix ...................................... 78


  © GBI Research. This is a licensed product and is not to be photocopied                                                                                        GBIHC255MR / Published OCT 2012
                                                                                                                                                                                          Page 7
Table of Contents




                                                  7.1      Market Definitions......................................................................................................................... 78
                                                  7.2      Abbreviations ................................................................................................................................ 78
                                                  7.3      Bibliography .................................................................................................................................. 79
                                                  7.4      Research Methodology ................................................................................................................. 80
                                                      7.4.1      Coverage ............................................................................................................................... 80
                                                      7.4.2      Secondary Research .............................................................................................................. 81
                                                      7.4.3      Primary Research .................................................................................................................. 81
                                                      7.4.4      Expert Panel Validation ......................................................................................................... 81
                                                  7.5      Contact Us ..................................................................................................................................... 82
                                                  7.6      Disclaimer ...................................................................................................................................... 82


                                              1.1       List of Tables
                                              Table 1:        Biopharmaceutical Manufacturing in India, China and South Korea, Biopharmaceutical
                                                              Approvals, the US, 2012 ............................................................................................................... 12
                                              Table 2:        Biopharmaceutical Manufacturing in India, China and South Korea, Biopharmaceuticals
                                                              Approved, the US, 2011................................................................................................................ 15
                                              Table 3:        Biopharmaceutical Manufacturing in India, China and South Korea, Biopharmaceuticals
                                                              Approved, the US, 2010................................................................................................................ 16
                                              Table 4:        Biopharmaceutical Manufacturing in India, China and South Korea, Geographical Distribution of
                                                              Cell Culture Capacity (000’ liters), 2011-2017 .............................................................................. 18
                                              Table 5:        Biopharmaceutical Manufacturing in India, China and South Korea, Volume Requirement for
                                                              Different Biopharmaceuticals, (000’ liters), 2011-2017 ............................................................... 19
                                              Table 6:        Biopharmaceutical Manufacturing, Product Demand Distribution in Monoclonal Antibodies (%),
                                                              Global, 2011 ................................................................................................................................. 20
                                              Table 7:        Biopharmaceutical Manufacturing, Global Sales of Leading Biologics and Year of Patent Expiry in
                                                              the US and Europe ........................................................................................................................ 21
                                              Table 8:        Biopharmaceutical Manufacturing, Comparative Cost Analysis Between In-House
                                                              Biopharmaceutical Production Versus CMOs, Global, 2011 ......................................................... 23
                                              Table 9:        Biopharmaceutical Manufacturing in India, China and South Korea, Contract Manufacturing and
                                                              the Drug Discovery and Research Market, Global, 2007-2016 ..................................................... 24
                                              Table 10:       Biopharmaceutical Manufacturing, Labor Cost Analysis Comparison ($), the US, Europe, India,
                                                              China, 2011 ................................................................................................................................... 27
                                              Table 11:       Biopharmaceutical Manufacturing in India, China and South Korea, Investment Range for
                                                                                                                                   3                  3
                                                              Manufacturing Plant Locations, Unit Cost per m ($), per m Reactor Volume, 2011 ................. 28
                                              Table 12:       Biopharmaceutical Manufacturing in India, China and South Korea, Average Cost for Product
                                                              Development Activity, ($’000) ...................................................................................................... 31
                                              Table 13:       Biopharmaceutical Manufacturing in India, China and South Korea, Major Products
                                                              Manufactured in India, with Segmentation, 2011 ........................................................................ 45
                                              Table 14:       Biopharmaceutical Manufacturing in India, China and South Korea, Market for Vaccines in India
                                                              ($m), 2011-2016 ........................................................................................................................... 46
                                              Table 15:       Biopharmaceutical Manufacturing in India, China and South Korea, Biopharmaceutical Market in
                                                              India ($bn), 2008-2016 ................................................................................................................. 47
                                              Table 16:       Biopharmaceutical Manufacturing in India, China and South Korea, Pharmaceutical and
                                                              Biopharmaceutical Market ($bn), China, 2011-2015.................................................................... 58
                                              Table 17:       Biopharmaceutical Manufacturing in India, China and South Korea, Different Categories of
                                                              Biopharmaceuticals, Expression System and Indications, China, 2011 ........................................ 59
                                              Table 18:       Biopharmaceutical Manufacturing in India, China and South Korea, Innovative
                                                              Biopharmaceutical Products, Indications, KFDA Approval Year and Company, 1999-2011 ......... 69
                                              Table 19:       Biopharmaceutical Manufacturing in India, China and South Korea, Biopharmaceutical Market,
                                                              South Korea ($bn), 2011-2016 ..................................................................................................... 70
                                              Table 20:       Biopharmaceutical Manufacturing in India, China and South Korea, Major R&D Achievements in
                                                              South Korea .................................................................................................................................. 72




  © GBI Research. This is a licensed product and is not to be photocopied                                                                                         GBIHC255MR / Published OCT 2012
                                                                                                                                                                                           Page 8
Table of Contents




                                              1.2      List of Figures
                                              Figure 1:    Biopharmaceutical Manufacturing, Number of FDA Approved Biopharmaceuticals, the US, 1982-
                                                           2011.............................................................................................................................................. 13
                                              Figure 2:    Biopharmaceutical Manufacturing, Percentage Share of Biopharmaceuticals in the Global
                                                           Pharmaceutical Market, 2001-2011 ............................................................................................. 14
                                              Figure 3:    Biopharmaceutical Manufacturing, Global, Production Capacity by Company (%), 2011 ........... 17
                                              Figure 4:    Biopharmaceutical Manufacturing in India, China and South 
				
DOCUMENT INFO
Shared By:
Tags:
Stats:
views:41
posted:12/4/2012
language:English
pages:82
Description: The report provides an analysis of biopharmaceuticals approved in 2010 and 2011, operating dynamics in the biopharmaceutical industry, the current scenario in biopharmaceutical manufacturing, key stakeholders, the current market size (2011) of biopharmaceuticals, and forecasts to 2016 for India, China, South Korea and the global market. The report also presents trends witnessed in biopharmaceutical manufacturing, preferred partnership pricing models, contract manufacturing partnerships, comparative analysis of biopharmaceutical manufacturing in India, China and South Korea, and the competitive landscape for the countries covered in the report.
BUY THIS DOCUMENT NOW PRICE: $3500 100% MONEY BACK GUARANTEED
PARTNER GBI Research
GBI Research is a market-leading provider of business intelligence reports. GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders’ insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs. Headquartered in the UK, the company has branches in the US and Asia, and provides world class client support and service.